Pursuant to Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, please find attached the Unaudited Financial Results for the quarter and half year ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries filed its Q2 FY26 and H1 FY26 results on 18 October 2025. Standalone revenue from operations for the quarter came in at around Rs. 169 crore versus ~Rs. 117 crore in Q2 FY25, reflecting ~45% year-on-year growth, while H1 FY26 revenue grew roughly 36% YoY. Net profit for the quarter showed strong growth versus the year-ago period. The company has adopted Indian Accounting Standards (Ind AS) for the first time with a transition date of 1 April 2024, causing prior period figures to be restated. Auditor NGST & Associates issued an unmodified (clean) review opinion on both standalone and consolidated results.
Strong top-line growth and clean auditor opinion are positive signals. Shareholders should note multiple growth initiatives: a Dubai subsidiary acquisition (Cibachem General Trading LLC), a binding agreement to acquire an API manufacturing facility in Telangana from Srigen Lifesciences for Rs. 25.5 crore, and BSE in-principle approval for a USD 15 million FCCB issue as part of a larger Rs. 1,500 crore fundraise plan, which could lead to dilution depending on the route chosen.